

DAFTAR PUSTAKA

- Ackermann, M., Verleden, S.E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., et al., 2020. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N. Engl. J. Med.* 383: 120–128.
- Alfaddagh, A., Martin, S.S., Leucker, T.M., Michos, E.D., Blaha, M.J., Lowenstein, C.J., et al., 2020. Inflammation and cardiovascular disease: From mechanisms to therapeutics. *Am. J. Prev. Cardiol.* 4: 100130.
- Anzai, A., Choi, J.L., He, S., Fenn, A.M., Nairz, M., Rattik, S., et al., 2017. The infarcted myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes. *J. Exp. Med.* 214: 3293–3310.
- Apostolakis, S., Vogiatzi, K., Amanatidou, V., & Spandidos, D.A., 2009. Interleukin 8 and cardiovascular disease. *Cardiovasc. Res.* 84: 353–360. doi:10.1093/cvr/cvp241
- Aziz, M., Fatima, R., & Assaly, R., 2020. Elevated interleukin-6 and severe COVID-19: A meta-analysis. *J. Med. Virol.* 92: 2283–2285. doi:10.1002/jmv.25948
- Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., et al., 2020. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* 583: 830–833.
- Baune, B.T., Rothermundt, M., Ladwig, K.H., Meisinger, C., & Berger, K., 2011. Systemic inflammation (Interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study. *Age (Omaha)*. 33: 209–217.
- Bhatla, A., Mayer, M.M., Adusumalli, S., Hyman, M.C., Oh, E., Tierney, A., et al., 2020. COVID-19 and cardiac arrhythmias. *Hear. Rhythm* 17: 1439–1444.
- Bikdeli, B., Madhavan, M. V, Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., et al., 2020. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. *J. Am. Coll. Cardiol.* 75: 2950–2973.
- Burhan, E., Susanto, A, D., Nasution, S,A., Ginanjar, E., Pitoyo, C, W., Susilo, A., Firdaus, I., Santoso, A., Juzar, D,A., Arif, S, K., Wulung, N, G, H, L., Adityaningsih, D., Syam, A, F., Rasmin, M., Rengganis, I., Sukrisman, L., Damayanti, T., Wiyono, W, H., Prasenhadi., Isbaniah, F., Elhidsi, M., Aniwidyaningsih, W. 2022. Pedoman Tatalaksana COVID-19, edisi 4, diterbitkan bersama PDPI, PERKI, PAPDI, PERDATIN, IDAI, Jakarta.
- Carsana, L., Sonzogni, A., Nasr, A., Rossi, R.S., Pellegrinelli, A., Zerbi, P., et al., 2020. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet Infect. Dis.* 20: 1135–1140.
- Cevik, M., Kuppalli, K., Kindrachuk, J., & Peiris, M., 2020. Virology, transmission, and pathogenesis of SARS-CoV-2. *BMJ* 371: 1–6.

doi:10.1136/bmj.m3862

- Cevik, M., Marcus, J.L., Buckee, C., & Smith, T.C., 2021. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission dynamics should inform policy. *Clin. Infect. Dis.* 73: S170–S176.
- Cevik, M., Tate, M., Lloyd, O., Maraolo, A.E., & Scahfers, J., n.d. A. Ho (2020). SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *The Lancet Microbe* 20: 30172–30175.
- Chandrashekar, A., Liu, J., Martinot, A.J., McMahan, K., Mercado, N.B., Peter, L., et al., 2020. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science (80-.)*. 369: 812–817.
- Chen, L.Y.C., Hoiland, R.L., Stukas, S., Wellington, C.L., & Sekhon, M.S., 2020. Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. *Eur. Respir. J.* 56. doi:10.1183/13993003.03006-2020
- Chen, T., Wu, D.I., Chen, H., Yan, W., Yang, D., Chen, G., et al., 2020. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *bmj* 368.
- Chin, A.W.H., Chu, J.T.S., Perera, M.R.A., Hui, K.P.Y., Yen, H.-L., Chan, M.C.W., et al., 2020. Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe* 1: e10.
- Choy, E., & Rose-John, S., 2017. Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. *J. Scleroderma Relat. Disord.* 2: S1–S5.
- Clerkin, K.J., Fried, J.A., Raikhelkar, J., Sayer, G., Griffin, J.M., Masoumi, A., et al., 2020. COVID-19 and Cardiovascular Disease. *Circulation* 2019: 1648–1655. doi:10.1161/CIRCULATIONAHA.120.046941
- Colon, C.M., Barrios, J.G., Chiles, J.W., McElwee, S.K., Russell, D.W., Maddox, W.R., et al., 2020. Atrial arrhythmias in COVID-19 patients. *Clin. Electrophysiol.* 6: 1189–1190.
- Cueto-Manzano, A.M., Espinel-Bermúdez, M.C., Hernández-González, S.O., Rojas-Campos, E., Nava-Zavala, A.H., Fuentes-Orozco, C., et al., 2021. Risk factors for mortality of adult patients with COVID-19 hospitalised in an emerging country: a cohort study. *BMJ Open* 11: e050321.
- Cui, J., Li, F., & Shi, Z.-L., 2019. Origin and evolution of pathogenic coronaviruses. *Nat. Rev. Microbiol.* 17: 181–192.
- da Rosa Mesquita, R., Francelino Silva Junior, L.C., Santos Santana, F.M., Farias de Oliveira, T., Campos Alcântara, R., Monteiro Arnozo, G., et al., 2021. Clinical manifestations of COVID-19 in the general population: systematic review. *Wien. Klin. Wochenschr.* 133: 377–382. doi:10.1007/s00508-020-01760-4
- De Rosa, S., Spaccarotella, C., Basso, C., Calabrò, M.P., Curcio, A., Filardi, P.P., et al., 2020. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. *Eur. Heart J.* 41: 2083–2088.

- Del Valle, D.M., Kim-Schulze, S., Huang, H.-H., Beckmann, N.D., Nirenberg, S., Wang, B., et al., 2020. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat. Med.* 26: 1636–1643.
- Deng, Q., Hu, B., Zhang, Y., Wang, H., Zhou, X., Hu, W., et al., 2020. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. *Int. J. Cardiol.* 311: 116–121.
- Dessie, Z.G., & Zewotir, T., 2021. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. *BMC Infect. Dis.* 21: 1–28.
- Docherty, A.B., Harrison, E.M., Green, C.A., Hardwick, H.E., Pius, R., Norman, L., et al., 2020. ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *Bmj* 369: m1985.
- Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S., 2009. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. *Nat. Rev. Microbiol.* 7: 226–236.
- Du, R.-H., Liang, L.-R., Yang, C.-Q., Wang, W., Cao, T.-Z., Li, M., et al., 2020. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur. Respir. J.* 55.
- Elezkurtaj, S., Greuel, S., Ihlow, J., Michaelis, E.G., Bischoff, P., Kunze, C.A., et al., 2021. Causes of death and comorbidities in hospitalized patients with COVID-19. *Sci. Rep.* 11: 1–9.
- Eljilany, I., & Elzouki, A.-N., 2020. D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review. *Vasc. Health Risk Manag.* 16: 455.
- Epelman, S., Liu, P.P., & Mann, D.L., 2015. Role of innate and adaptive immune mechanisms in cardiac injury and repair. *Nat. Rev. Immunol.* 15: 117–129.
- Fisman, E.Z., Benderly, M., Esper, R.J., Behar, S., Boyko, V., Adler, Y., et al., 2006. Interleukin-6 and the Risk of Future Cardiovascular Events in Patients With Angina Pectoris and/or Healed Myocardial Infarction. *Am. J. Cardiol.* 98: 14–18. doi:10.1016/j.amjcard.2006.01.045
- Fried, J.A., Ramasubbu, K., Bhatt, R., Topkara, V.K., Clerkin, K.J., Horn, E., et al., 2020. The variety of cardiovascular presentations of COVID-19. *Circulation* 141: 1930–1936.
- Gager, G.M., Biesinger, B., Hofer, F., Winter, M.P., Hengstenberg, C., Jilma, B., et al., 2020. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. *Vascul. Pharmacol.* 135: 106806. doi:10.1016/j.vph.2020.106806
- Glezeva, N., & Baugh, J.A., 2014. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. *Heart Fail. Rev.* 19: 681–694.

- Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., et al., 2020. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *Jama* 323: 1574–1581.
- Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., et al., 2020. Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* 382: 1708–1720.
- Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., et al., 2020. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* 5: 811–818.
- Gwechenberger, M., Mendoza, L.H., Youker, K.A., Frangogiannis, N.G., Smith, C.W., Michael, L.H., et al., 1999. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. *Circulation* 99: 546–551.
- Han, H., Ma, Q., Li, C., Liu, R., Zhao, L., Wang, W., et al., 2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect.* 2020; 9 (1): 1123–30.
- Held, C., White, H.D., Stewart, R.A.H., Budaj, A., Cannon, C.P., Hochman, J.S., et al., 2017. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial. *J. Am. Heart Assoc.* 6: e005077.
- Herman, H., Gharini, P.P.R., & Dinarti, L.K., 2020. Clinical cardiac manifestations in patients with coronavirus disease 2019 (COVID-19). *J. Med. Sci. (Berkala ilmu Kedokteran)* 52.
- Herold, T., Jurinovic, V., Arnreich, C., & Lipworth, B.J., 2020. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information.
- Hou, T., Huang, D., Zeng, R., Ye, Z., & Zhang, Y., 2015. Accuracy of serum interleukin (IL)-6 in sepsis diagnosis: a systematic review and meta-analysis. *Int. J. Clin. Exp. Med.* 8: 15238.
- Hu, B., Guo, H., Zhou, P., & Shi, Z.L., 2021. Characteristics of SARS-CoV-2 and COVID-19. *Nat. Rev. Microbiol.* 19: 141–154. doi:10.1038/s41579-020-00459-7
- Hu, H., Ma, F., Wei, X., & Fang, Y., n.d. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin [published online ahead of print March 16, 2020]. *Eur Hear. J.*
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395: 497–506. doi:10.1016/S0140-6736(20)30183-5
- Italia, L., Tomasoni, D., Bisegna, S., Pancaldi, E., Stretti, L., Adamo, M., et al., 2021. COVID-19 and heart failure: from epidemiology during the

- pandemic to myocardial injury, myocarditis, and heart failure sequelae. *Front. Cardiovasc. Med.* 867.
- Jin, Z., Niu, J., Kapoor, N., Liang, J., Becerra, E., & Kolattukudy, P.E., 2019. Essential role of endothelial MCP-1 in vascular integrity and post-ischemic remodeling. *Int. J. Mol. Sci.* 20: 172.
- Joly, B.S., Siguret, V., & Veyradier, A., 2020. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. *Intensive Care Med.* 46: 1603–1606.
- Jouline, O., Petillot, P., Labalette, M., Lancel, S., & Neviere, R., 2007. Cytokine profile of human septic shock serum inducing cardiomyocyte contractile dysfunction. *Physiol. Res.* 56: 291.
- Kanda, T., & Takahashi, T., 2004. Interleukin-6 and cardiovascular diseases. *Jpn. Heart J.* 45: 183–193.
- Kang, Y., Chen, T., Mui, D., Ferrari, V., Jagasia, D., Scherrer-Crosbie, M., et al., 2020. Cardiovascular manifestations and treatment considerations in COVID-19. *Heart* 106: 1132–1141. doi:10.1136/heartjnl-2020-317056
- Khalid, N., Chen, Y., Case, B.C., Shlofmitz, E., Wermers, J.P., Rogers, T., et al., 2020. COVID-19 (SARS-Cov-2) and the heart—An ominous association. *Cardiovasc. Revascularization Med.* 21: 946–949.
- Klompas, M., Baker, M.A., & Rhee, C., 2020. Airborne transmission of SARS-CoV-2: theoretical considerations and available evidence. *Jama* 324: 441–442.
- Kubota, T., Miyagishima, M., Alvarez Jr, R.J., Kormos, R., Rosenblum, W.D., Demetris, A.J., et al., 2000. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. *J. Hear. lung Transplant.* 19: 819–824.
- Kucirka, L.M., Lauer, S.A., Laeyendecker, O., Boon, D., & Lessler, J., 2020. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. *Ann. Intern. Med.* 173: 262–267.
- KuiLiu, Y.-Y.F., & Deng, Y., 2020. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin. Med. J. (Engl.)*.
- Laguna-goya, R., Utrero-rico, A., Talayero, P., Lasa-lazaro, M., Aguado, J.M., & Martinez-lopez, J., 2020. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information .
- Lakkireddy, D.R., Chung, M.K., Gopinathannair, R., Patton, K.K., Gluckman, T.J., Turagam, M., et al., 2020. Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; electrophysiology section of

- the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on. *Circulation* 141: e823–e831.
- Li, J., Huang, D.Q., Zou, B., Yang, H., Hui, W.Z., Rui, F., et al., 2021. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. *J. Med. Virol.* 93: 1449–1458.
- Liu, T., Zhang, Jieying, Yang, Y., Ma, H., Li, Z., Zhang, Jiaoyue, et al., 2020. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. *EMBO Mol. Med.* 12: 1–12. doi:10.15252/emmm.202012421
- Liu, Y., Gayle, A.A., Wilder-Smith, A., & Rocklöv, J., 2020. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J. Travel Med.*
- Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., et al., 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 395: 565–574.
- Madjid, M., Safavi-Naeini, P., Solomon, S.D., & Vardeny, O., 2020. Potential effects of coronaviruses on the cardiovascular system: a review. *JAMA Cardiol.* 5: 831–840.
- Mai, F., Del Pinto, R., & Ferri, C., 2020. COVID-19 and cardiovascular diseases. *J. Cardiol.* 76: 453–458. doi:10.1016/j.jjcc.2020.07.013
- Mandel, M., Harari, G., Gurevich, M., & Achiron, A., 2020. Cytokine prediction of mortality in COVID19 patients. *Cytokine* 134: 155190. doi:10.1016/j.cyto.2020.155190
- Mann, D.L., 2015. Innate immunity and the failing heart: the cytokine hypothesis revisited. *Circ. Res.* 116: 1254–1268.
- Mann, D.L., Topkara, V.K., Evans, S., & Barger, P.M., 2010. Innate immunity in the adult mammalian heart: for whom the cell tolls. *Trans. Am. Clin. Climatol. Assoc.* 121: 34.
- Martines, R.B., Ritter, J.M., Matkovic, E., Gary, J., Bollweg, B.C., Bullock, H., et al., 2020. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. *Emerg. Infect. Dis.* 26: 2005.
- Mehra, M.R., & Ruschitzka, F., 2020. COVID-19 illness and heart failure: a missing link? *Heart Fail.*
- Menéndez, R., Sahuquillo-Arce, J.M., Reyes, S., Martínez, R., Polverino, E., Cillóniz, C., et al., 2012. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. *Chest* 141: 1537–1545.
- Murphy, S.P., Kakkar, R., McCarthy, C.P., & Januzzi Jr, J.L., 2020. Inflammation in heart failure: JACC state-of-the-art review. *J. Am. Coll. Cardiol.* 75: 1324–1340.
- Nguyen, N., Nguyen, H., Ukoha, C., Hoang, L., Patel, C., Ikram, F.G., et al.,

2022. Relation of interleukin-6 levels in COVID-19 patients with major adverse cardiac events, in: Baylor University Medical Center Proceedings. Taylor & Francis, pp. 6–9.
- Nishiga, M., Wang, D.W., Han, Y., Lewis, D.B., & Wu, J.C., 2020. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. *Nat. Rev. Cardiol.* 17: 543–558. doi:10.1038/s41569-020-0413-9
- Onder, G., Palmieri, L., Vanacore, N., Giuliano, M., & Brusaferrero, S., 2021. The Italian National Institute of Health COVID-19 mortality group. *Nonrespir. Complicat. Obes. Patients Dying with COVID-19 Italy. Obes.* 29: 20–23.
- Palmieri, L., Vanacore, N., Donfrancesco, C., Lo Noce, C., Canevelli, M., Punzo, O., et al., 2020. Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy. *Journals Gerontol. Ser. A* 75: 1796–1800.
- Panigada, M., Bottino, N., Tagliabue, P., Grasselli, G., Novembrino, C., Chantarangkul, V., et al., 2020. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. *J. Thromb. Haemost.* 18: 1738–1742.
- Patel, V.B., Zhong, J.-C., Grant, M.B., & Oudit, G.Y., 2016. Role of the ACE2/angiotensin 1–7 axis of the renin–angiotensin system in heart failure. *Circ. Res.* 118: 1313–1326.
- Paulus, W.J., & Tschöpe, C., 2013. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J. Am. Coll. Cardiol.* 62: 263–271.
- Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon III, R.O., Criqui, M., et al., 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 107: 499–511.
- Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A., & Ozben, T., 2020. Biomarkers associated with COVID-19 disease progression. *Crit. Rev. Clin. Lab. Sci.* 57: 389–399. doi:10.1080/10408363.2020.1770685
- Pranata, R., Huang, I., & Raharjo, S.B., 2020. Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. *Indian Pacing Electrophysiol. J.* 20: 193–198.
- Pudil, R., Tichý, M., Andráš, C., Reháček, V., Bláha, V., Vojáček, J., et al., 2010. Plasma interleukin-6 level is associated with NT-proBNP level and predicts short-and long-term mortality in patients with acute heart failure. *Acta Medica (Hradec Kral.* 53: 225–228.
- Rai, H., Colleran, R., Cassese, S., Joner, M., Kastrati, A., & Byrne, R.A., 2021. Association of interleukin 6-174 G/C polymorphism with

coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis. *Inflamm. Res.* 70: 1075–1087.

- Ridker, P.M., Rifai, N., Stampfer, M.J., & Hennekens, C.H., 2000. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation* 101: 1767–1772. doi:10.1161/01.CIR.101.15.1767
- Rodriguez-Leor, O., Cid-Álvarez, B., Ojeda, S., Martín-Moreiras, J., Rumoroso, J.R., López-Palop, R., et al., 2020. Impact of the COVID-19 pandemic on interventional cardiology activity in Spain. *REC Interv Cardiol* 2: 82–89.
- Roldán, V., Marín, F., Blann, A.D., García, A., Marco, P., Sogorb, F., et al., 2003. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. *Eur. Heart J.* 24: 1373–1380.
- Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., et al., 2020. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. *N. Engl. J. Med.* 382: 970–971.
- Sabaka, P., Koščálová, A., Straka, I., Hodosy, J., Lipták, R., Kmotorková, B., et al., 2021. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. *BMC Infect. Dis.* 21: 4–11. doi:10.1186/s12879-021-05945-8
- Santa Cruz, A., Mendes-Frias, A., Oliveira, A.I., Dias, L., Matos, A.R., Carvalho, A., et al., 2021. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. *Front. Immunol.* 12: 1–10. doi:10.3389/fimmu.2021.613422
- Santoso, A., Pranata, R., Wibowo, A., Al-Farabi, M.J., Huang, I., & Antariksa, B., 2021. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. *Am. J. Emerg. Med.* 44: 352–357.
- Sarwar, N., Butterworth, A.S., Freitag, D.F., Gregson, J., Willeit, P., Gorman, D.N., et al., 2012. Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies. *Lancet* 379: 1205–1213. doi:10.1016/S0140-6736(11)61931-4
- Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., et al., 2020. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. *Science (80-.)*. 368: 1016–1020.
- Shlipak, M.G., Ix, J.H., Bibbins-Domingo, K., Lin, F., & Whooley, M.A., 2008. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. *Am. J. Med.* 121: 50–57.
- Singhal, T., 2020. Review on COVID19 disease so far. *Indian J. Pediatr.* 87: 281–286.
- Sorriento, D., & Iaccarino, G., 2019. Inflammation and cardiovascular diseases: the most recent findings. *Int. J. Mol. Sci.*
- Stefanini, G.G., Montorfano, M., Trabattoni, D., Andreini, D., Ferrante, G.,

- Ancona, M., et al., 2020. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. *Circulation* 141: 2113–2116.
- Su, D., Li, Z., Li, X., Chen, Y., Zhang, Y., Ding, D., et al., 2013. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. *Mediators Inflamm.* 2013. doi:10.1155/2013/726178
- Tanaka, T., Narazaki, M., & Kishimoto, T., 2014. IL-6 in Inflammation, Immunity, and Disease 6.
- Team, E., 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. *China CDC Wkly.* 2: 113.
- Tomasoni, D., Italia, L., Adamo, M., Inciardi, R.M., Lombardi, C.M., Solomon, S.D., et al., 2020. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. *Eur. J. Heart Fail.* 22: 957–966.
- Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L.L., & Borca, M. V, 2019. The role of interleukin 6 during viral infections. *Front. Microbiol.* 10: 1057.
- Volpato, S., Guralnik, J.M., Ferrucci, L., Balfour, J., Chaves, P., Fried, L.P., et al., 2001. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. *Circulation* 103: 947–953.
- Wainstein, M. V, Mossmann, M., Araujo, G.N., Gonçalves, S.C., Gravina, G.L., Sangalli, M., et al., 2017. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. *Diabetol. Metab. Syndr.* 9: 1–7.
- Walls, A.C., Park, Y.-J., Tortorici, M.A., Wall, A., McGuire, A.T., & Velesler, D., 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 181: 281–292.
- Wan, Y., Shang, J., Graham, R., Baric, R.S., & Li, F., 2020. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. *J. Virol.* 94: e00127-20.
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al., 2020. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J. Am. Med. Assoc.* 323: 1061–1069. doi:10.1001/jama.2020.1585
- Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., et al., 2020. Detection of SARS-CoV-2 in different types of clinical specimens. *Jama* 323: 1843–1844.
- Wichmann, D., Sperhake, J.-P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., et al., 2020. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort

- study. *Ann. Intern. Med.* 173: 268–277.
- World Health Organization. <https://covid19.who.int/>.
- Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J., & Prescott, H.C., 2020. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - J. Am. Med. Assoc. American Medical Association*. doi:10.1001/jama.2020.12839
- Willerson, J.T., & Ridker, P.M., 2004. Inflammation as a cardiovascular risk factor. *Circulation* 109: II–2.
- Wollert, K.C., & Drexler, H., 2001. The role of interleukin-6 in the failing heart. *Heart Fail. Rev.* 6: 95–103.
- Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.-L., Abiona, O., et al., 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science (80-.)*. 367: 1260–1263.
- Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., et al., 2020. A new coronavirus associated with human respiratory disease in China. *Nature* 579: 265–269.
- Wu, Z., & McGoogan, J.M., 2020. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. *JAMA - J. Am. Med. Assoc.* 323: 1239–1242. doi:10.1001/jama.2020.2648
- Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al., 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* 8: 420–422.
- Yadaw, A.S., Li, Y., Bose, S., Iyengar, R., Bunyavanich, S., & Pandey, G., 2020. Clinical predictors of COVID-19 mortality. *medRxiv*.
- Yang, J., Zheng, Y., Gou, X., Pu, K., & Chen, Z., 2020. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int. J. Infect. Dis.* 94: 91–95.
- Yang, Y., Lv, J., Jiang, S., Ma, Z., Wang, D., Hu, W., et al., 2016. The emerging role of Toll-like receptor 4 in myocardial inflammation. *Cell Death Dis.* 7: e2234–e2234.
- Zeng, Z., Xu, L., Xie, X., Yan, H., Xie, B., Xu, W., et al., 2020. Pulmonary pathology of early-phase COVID-19 pneumonia in a patient with a benign lung lesion. *Histopathology* 77: 823–831.
- Zhang, B., Li, X.L., Zhao, C.R., Pan, C.L., & Zhang, Z., 2018. Interleukin-6 as a Predictor of the Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Epidemiological Studies. *Immunol. Invest.* 47: 689–699. doi:10.1080/08820139.2018.1480034
- Zhang, H., Penninger, J.M., Li, Y., Zhong, N., & Slutsky, A.S., 2020. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med.* 46: 586–590.

- Zhang, Y., Bauersachs, J., & Langer, H.F., 2017. Immune mechanisms in heart failure. *Eur. J. Heart Fail.* 19: 1379–1389.
- Zhao, X., Chen, D., Szabla, R., Zheng, M., Li, G., Du, P., et al., 2020. Broad and differential animal angiotensin-converting enzyme 2 receptor usage by SARS-CoV-2. *J. Virol.* 94: e00940-20.
- Zheng, Y Y, Ma, Y.T., Zhang, J.Y., & COVID, X.X., 2020. and the cardiovascular system *Nat. Rev. Cardiol* 17: 259–260.
- Zheng, Ying Ying, Ma, Y.T., Zhang, J.Y., & Xie, X., 2020. COVID-19 and the cardiovascular system. *Nat. Rev. Cardiol.* 17: 259–260. doi:10.1038/s41569-020-0360-5
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 395: 1054–1062.
- Zhou, J., He, W., Liang, J., Wang, L., Yu, X., Bao, M., et al., 2020. Association of interleukin-6 level with morbidity and mortality in patients with coronavirus disease 2019 (COVID-19). *Jpn J Infect Dis.*
- Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579: 270–273.
- Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., et al., 2020. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N. Engl. J. Med.* 382: 1177–1179.
- Zou, X., Chen, K., Zou, J., Han, P., & Hao, J., 2020. han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med* 14: 185–192.